Research programme: anthrax therapies - BasileaAlternative Names: Antifolates for anthrax - Basilea; Dihydrofolate reductase inhibitors for anthrax - Basilea; Dihydrophtalazines - Basilea
Latest Information Update: 06 Jul 2011
At a glance
- Originator Basilea Pharmaceutica
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anthrax
Most Recent Events
- 28 Feb 2006 Preclinical trials in Anthrax in USA (unspecified route)
- 28 Feb 2006 Preclinical trials in Anthrax in Switzerland (unspecified route)